Upper extremity deep vein thrombosis following BBIBP‐CorV COVID‐19 vaccine (Sinopharm vaccine): A case report

Key Clinical Message In patients with acute symptoms such as pain, swelling, and erythema of the upper extremities shortly after receiving COVID‐19 vaccines, even inactivated virus vaccines, these symptoms may indicate thrombosis, which may be due to the vaccination. Abstract BBIBP‐CorV COVID‐19 vac...

Full description

Bibliographic Details
Main Authors: Ali Riazi, Masood Faghih Dinevari, Samaneh Abbasian, Amirreza Jabbaripour Sarmadian
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Clinical Case Reports
Subjects:
Online Access:https://doi.org/10.1002/ccr3.7535
Description
Summary:Key Clinical Message In patients with acute symptoms such as pain, swelling, and erythema of the upper extremities shortly after receiving COVID‐19 vaccines, even inactivated virus vaccines, these symptoms may indicate thrombosis, which may be due to the vaccination. Abstract BBIBP‐CorV COVID‐19 vaccine (Sinopharm vaccine) is an inactivated whole virus vaccine to control the COVID‐19 pandemic. Studies concluded that inactivated COVID‐19 vaccines do not increase the risk of thrombosis. This report presents a 23‐year‐old man with the chief complaint of severe pain, swelling, and erythema of the right upper extremity following his second dose of the Sinopharm vaccine. Duplex ultrasound of the right upper extremity revealed upper extremity deep vein thrombosis, and treatment started with oral anticoagulation. It is probably the first upper extremity deep vein thrombosis case following inactivated COVID‐19 vaccines.
ISSN:2050-0904